Alfonso Tafur: Different Cancer Sites Drive Different Thrombotic Phenotypes
Alfonso Tafur, Vascular Medicine Fellowship Program Director at University of Chicago, Director of Vascular Medicine Department at NorthShore University, shared on LinkedIn:
”For years, many of us have treated cancer-associated thrombosis as if it were a single disease.
The data keep reminding us: it isn’t.
In the RIETE Registry, we looked at 18,000+ cancer patients vs. 88,000 without.
Within 90 days — 2.5× higher recurrent VTE, ~40% higher major bleeding.
But the real signal? Cancer site matters.
Lung and pancreatic drive clot risk. GI and GU drive bleeding risk.
Cancer-associated thrombosis is not one disease.
It is many biologically different thrombotic phenotypes.
Proud to be part of this team working toward precision vascular care.”
Proceed to the video attached to the post.
Stay updated with Hemostasis Today.
-
Aug 11, 2026, 07:50When Access to Care Changes Everything – WFH
-
Aug 11, 2026, 07:41Kevin Land: How Cellular Therapy Is Changing Transfusion Medicine
-
Aug 11, 2026, 07:35Kuldeep Singh Bhadauria: Building the Future of Hemophilia Care in India
-
Aug 11, 2026, 07:28Archil Jaliashvili: When Every Minute Matters Time Becomes a Therapy
-
Aug 11, 2026, 07:05Mavis Agnes Kisakye: Building Sustainable Transition Pathways in Hemophilia Care
-
Aug 11, 2026, 06:48Rishdha Roshad: What Happens to the Brain During Cardiopulmonary Bypass?
-
Aug 11, 2026, 05:53Isaac Okello: Strengthening Sickle Cell Advocacy in Uganda
-
Aug 11, 2026, 05:38Rami Unterman: A Simple New Biomarker for Fibrotic ILDs
-
Aug 11, 2026, 04:10Haroun Gajraj: CLaCS vs Sclerotherapy – What Does the Evidence Show